English, PDF, 566kb
This report presents findings from a pilot survey of business activity in nanotechnology and discusses methodological and practical issues (e.g. the use of definitions) for on-going consideration in work on statistics and indicators for nanotechnology. It identifies how work in this area may support the assessment of other emerging technologies via an integrated framework.
This report examines examples of new and emerging governance models that aim to support the responsible development of diagnostics and treatments based on the latest advances in biomedicine. In particular, it presents programmes and initiatives that aim to manage uncertainty in the development and approval of new medical products and thereby to improve the understanding of the risk/benefit balance.
The economic and social impact of chronic brain disorders such as Alzheimer’s disease and other neurodegenerative diseases will become the number one public-health problem worldwide, directly affecting 100 million people by 2050.
This paper explores the development of the bioplastics sector and its role in national bioeconomy strategies. It finds that bioplastics are at a disadvantage compared to some other biobased products, notably biofuels, that often benefit from preferential treatment. It also notes that greater efforts are needed at the international level as regards standards to avoid creating barriers to international trade in biobased products.
English, PDF, 1,992kb
Governments have a fiscal and social responsibility to ensure that limited research and development resources are used wisely and cost-effectively in support of social, economic, and scientific aspirations. Countries that wish to promote the continued responsible development of nanotechnology will, however, need quantitative data on the economic impact of nanotechnology to guide further investment and policy decisions.
This book discusses scientific and technological tools at the centre of a renewed interest in marine biotechnology that is contributing to a new bioeconomy sector in many countries and offering potential new solutions to global challenges.
This report presents the findings of a research project to investigate the drivers and criteria shaping the application of genomic biotechnology to health in different national settings, and the barriers to implementation nationally and internationally. Findings are based on case studies on Finland, Israel, Luxembourg, Mexico, the United Kingdom, China and South Africa.
This paper brings together information collected through Working Party on Nanotechnology discussions and projects. It relies in particular on preliminary results from a project on the responsible development of nanotechnology and outcomes of a symposium held in 2012.
Environmental biotechnology is focused on clean-up and much of the policy in this area is around compliance, whereas industrial biotech has quite different policy objectives and only started to grow as a field with the worldwide interest in biofuels. Much of the world now has targets for bioenergy and favourable policy regimes to stimulate production and use of biofuels, but sustainability has become a real issue.
The OECD and the ESRC Genomics Policy & Research Forum jointly organised a one-day Forum on 12 November 2012 in Paris. The event was both retrospective and forward-looking. The forum concluded that the promise of biotechnology is not set but evolves with fresh scientific knowledge, novel laws and regulations. The future of biotechnology needs to also integrate social and cultural dimensions.